EA Electronic Arts Inc.

Venture into Danger with New IP from EA, Anthemâ„¢

Today, Electronic Arts Inc. (NASDAQ:EA) gave the world its first look at Anthem, the brand-new IP being created by BioWare. Anthem is a shared-world action-RPG, where players can delve into a vast world teeming with amazing technology and forgotten treasures. The world is also filled with savage beasts and ruthless marauders where Freelancers are called to defeat the forces plotting to conquer humanity.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170611005072/en/

Venture into Danger with New IP from EA, Anthem™ (Photo: Business Wire)

Venture into Danger with New IP from EA, Anthem™ (Photo: Business Wire)

“Our developers at BioWare have been creating something special," said Patrick Soderlund, Executive Vice President of EA Worldwide Studios. “We’re pushing Frostbite to new heights, developing a game unlike anything EA has ever made before. We’re telling a new story, creating a social, co-operative experience, and putting it in a contiguous open world that is dynamic and will be ever-changing for years to come."

In Anthem, up to four friends can unravel the world’s mysteries and take on its most fearsome challenges together. Shared danger means shared glory, and successful Freelancers will all be richly rewarded for successful exploits. Throughout their adventure, players can outfit their Freelancers with powerful Javelin exosuits, each of which are equipped with unique weapons and abilities. Players can also customize their Javelin with gear they earn and craft throughout the adventure, and leave a lasting mark on the world.

Those who want to learn more about Anthem are encouraged to check out the official website, and sign up for the Anthem newsletter to be the first to receive new details about the game.

About Electronic Arts

Electronic Arts (NASDAQ: EA) is a global leader in digital interactive entertainment. The Company delivers games, content and online services for Internet-connected consoles, personal computers, mobile phones and tablets. EA has more than 300 million registered players around the world.

In fiscal year 2017, EA posted GAAP net revenue of $4.8 billion. Headquartered in Redwood City, California, EA is recognized for a portfolio of critically acclaimed, high-quality blockbuster brands such as The Sims™, Madden NFL, EA SPORTS™ FIFA, Battlefield™, Need for Speed™, Dragon Age™ and Plants vs. Zombies™. More information about EA is available at www.ea.com/news.

Ultimate Team, EA SPORTS, Battlefield, Battlefield 4, The Sims, Need for Speed, Dragon Age, Plants vs. Zombies, BioWare, and Anthem are trademarks of Electronic Arts Inc. STAR WARS © & TM 2015, 2017 Lucasfilm Ltd. All rights reserved. John Madden, NFL and FIFA are the property of their respective owners and used with permission.

Xbox and Xbox 360 are trademarks of the Microsoft group of companies. "PlayStation" is a registered trademark of Sony Computer Entertainment Inc.

EN
11/06/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Electronic Arts Inc.

Wedbush Research
  • Wedbush Research
UBI UBISOFT ENTERTAINMENT SA
XNCR XENCOR INC.
XENE XENON PHARMACEUTICALS INC
WDC WESTERN DIGITAL CORPORATION
VYGR VOYAGER THERAPEUTICS INC.
TTWO TAKE-TWO INTERACTIVE SOFTWARE INC.
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
RARE ULTRAGENYX PHARMACEUTICAL INC.
PSTG PURE STORAGE INC. CLASS A
NVDA NVIDIA CORPORATION
NVCR NOVOCURE LTD.
NTAP NETAPP INC.
NKTR NEKTAR THERAPEUTICS
NBIX NEUROCRINE BIOSCIENCES INC.
MU MICRON TECHNOLOGY INC.
KURA KURA ONCOLOGY INC.
INTC INTEL CORPORATION
GOOGL ALPHABET INC. CLASS A
GERN GERON CORP.
FB FACEBOOK INC. CLASS A
FATE FATE THERAPEUTICS INC
CTMX CYTOMX THERAPEUTICS INC.
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
BCRX BIOCRYST PHARMACEUTICALS INC.
AXTI AXT INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ARDX ARDELYX INC
ACRS ACLARIS THERAPEUTICS INC.
CDR CD PROJEKT S.A.
FRX_CN FENNEC PHARMACEUTICALS
7974 NINTENDO CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
EA ELECTRONIC ARTS INC.
ANAB ANAPTYSBIO INC.
ARGX ARGENX ADS
OVID OVID THERAPEUTICS
ISR ISORAY
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
APLS APELLIS PHARMACEUTICALS
DNLI DENALI THERAPEUTICS INC
RCUS ARCUS BIOSCIENCES
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
REPL REPLIMUNE GROUP
ARVN ARVINAS HOLDING
STRO SUTRO BIOPHARMA
UBER UBER TECHNOLOGIES INC.
STOK STOKE THERAPEUTICS
SMCI SUPER MICRO COMPUTER
IDYA INC.
PASG IDEAYA BIOSCIENCES
BDTX PASSAGE BIO
ACET BLACK DIAMOND THERAPEUTICS
KROS ADICET BIO INC
ORIC KEROS THERAPEUTICS
ZNTL ORIC PHARMACEUTICALS
BEAM ZENTALIS PHARMACEUTICALS
LRMR BEAM THERAPEUTICS
PRAX LARIMAR THERAPEUTICS INC
U PRAXIS PRECISION MEDICINES
TVTX UNITY SOFTWARE
VRDN TRAVERE THERAPEUTICS INC
SANA VIRIDIAN THERAPEUTICS INC
PLTK SANA BIOTECHNOLOGY
RBLX PLAYTIKA HOLDING
DAWN ROBLOX
STX DAY ONE BIOPHARMACEUTICALS INC
APP SEAGATE TECHNOLOGY HLDGS PLC
GFS APPLOVIN CORP
GMTX GLOBALFOUNDRIES INC
TYRA GEMINI THERAPEUTICS INC
PEPG TYRA BIOSCIENCES INC
EWTX PEPGEN INC
SLDB EDGEWISE THERAPEUTICS INC
DDI SOLID BIOSCIENCES INC
APGE DOUBLEDOWN INTERACTIVE CO LTD
EMBRAC B APOGEE THERAPEUTICS INC
DNTH EMBRACER GROUP AB
ORKA DIANTHUS THERAPEUTICS INC
BCAX ORUKA THERAPEUTICS INC
ZBIO BICARA THERAPEUTICS INC.
TLX ZENAS BIOPHARMA INC.
MAZE TELIX PHARMACEUTICALS LIMITED
JBIO MAZE THERAPEUTICS INC
IMA JADE BIOSCIENCES INC
IMAGENEBIO INC.
Michael Piccolo
  • Michael Piccolo

Daily Recap: TRIP, PUIG/EL, JEF/8316, JHG/VCTR, EA, ZION, BLX, PERF, A...

INDUSTRY NEWS - Convertible Bonds: Record Average Deal Sizes as Nebius, Oracle Drive $30.3 Billion in YTD 2026 Issuance. According to Bloomberg, the U.S. convertible bond market is on pace for another blockbuster year, with year-to-date issuance reaching $30.3 billion through late March 2026; a 76%

Michael Piccolo
  • Michael Piccolo

Daily Recap: SSTK/GETY, BCRX, DSGR, AVAV, JHG/VCTR, MA, GIS, LNSR/ALC,...

BioCryst Pharmaceuticals, Inc. (BCRX - $9.30)Laura Chico's Thoughts On Betaville Rumors; Takeout Not Central To Our Thesis, But Possible; Remains OUTPERFORM. On Monday, Betaville published a potential comment indicating BCRX could be an M&A target for a US-listed biopharma over $15 billion. We

ResearchPool Subscriptions

Get the most out of your insights

Get in touch